NP
MRNA icon

NorthRock Partners’s Moderna MRNA Stock Holding History

NorthRock Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,195
Closed -$214K – 837
2024
Q3 		$214K Sell
3,195
-1,148
-26% -$105K 0.01% 591
2024
Q2 		$516K Buy
4,343
+418
+11% +$52.9K 0.02% 336
2024
Q1 		$418K Buy
3,925
+638
+19% +$64.3K 0.02% 404
2023
Q4 		$327K Buy
+3,287
New +$276K 0.01% 435
2023
Q2 		– Sell
-1,681
Closed -$258K – 335
2023
Q1 		$258K Sell
1,681
-394
-19% -$65K 0.03% 258
2022
Q4 		$373K Buy
+2,075
New +$339K 0.04% 201
2022
Q3 		– Sell
-1,820
Closed -$260K – 321
2022
Q2 		$260K Buy
1,820
+254
+16% +$36.3K 0.03% 249
2022
Q1 		$270K Buy
1,566
+193
+14% +$32.5K 0.02% 261
2021
Q4 		$349K Buy
1,373
+455
+50% +$133K 0.03% 216
2021
Q3 		$396K Buy
+918
New +$339K 0.03% 183

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

NorthRock Partners's MRNA Position: Q4 2024 in Review

NorthRock Partners sold out of Moderna (MRNA) in Q4 2024, closing a stake of 3,195 shares — an estimated $214K sold.

NorthRock Partners first reported a position in MRNA in Q3 2021 and held it in 10 quarters. The position peaked at $516K in Q2 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • NorthRock Partners reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • NorthRock Partners sold 3,195 Moderna shares in Q4 2024, an estimated $214K.
  • NorthRock Partners first reported a position in Moderna in Q3 2021 and held it in 10 quarters.
  • NorthRock Partners's Moderna position peaked at $516K in Q2 2024.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on NorthRock Partners's 13F filing for Q4 2024, filed 14 Feb 2025.